Australian Clinical Labs Ltd (ASX: ACL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Australian Clinical Labs Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Australian Clinical Labs Ltd (ASX: ACL)
Latest News
Healthcare Shares
3 small-cap ASX healthcare shares 'with strong prospects'
Share Market News
3 ASX All Ords shares with 'potential for strong future performance'
Healthcare Shares
ASX All Ords share higher despite major shareholder cashing out 30% stake
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Share Market News
These are the 10 most shorted ASX shares
Cheap Shares
'Undervalued': 3 ASX 300 shares to buy following significant share price falls
Share Market News
These are the 10 most shorted ASX shares
Frequently Asked Questions
-
Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.
-
Australian Clinical Labs generally pays its shareholder dividends in April and September.
-
Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
04 Sep 2024 | $0.0900 | 100.00% | Final | 27 Sep 2024 |
28 Mar 2024 | $0.0300 | 100.00% | Interim | 26 Apr 2024 |
27 Mar 2023 | $0.0700 | 100.00% | Interim | 26 Apr 2023 |
23 Aug 2022 | $0.4100 | 100.00% | Final | 15 Sep 2022 |
25 Mar 2022 | $0.1200 | 100.00% | Interim | 21 Apr 2022 |
ACL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Australian Clinical Labs Ltd
Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.
Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing.
In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.
ACL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
02 Dec 2024 | $3.46 | $-0.01 | -0.29% | 707,586 | $3.52 | $3.61 | $3.42 |
29 Nov 2024 | $3.47 | $-0.03 | -0.86% | 293,372 | $3.52 | $3.52 | $3.45 |
28 Nov 2024 | $3.50 | $0.00 | 0.00% | 459,245 | $3.48 | $3.52 | $3.46 |
27 Nov 2024 | $3.50 | $-0.04 | -1.13% | 651,675 | $3.47 | $3.59 | $3.47 |
26 Nov 2024 | $3.54 | $0.04 | 1.14% | 577,971 | $3.47 | $3.57 | $3.45 |
25 Nov 2024 | $3.50 | $0.00 | 0.00% | 569,231 | $3.50 | $3.54 | $3.45 |
22 Nov 2024 | $3.50 | $0.03 | 0.86% | 284,112 | $3.44 | $3.53 | $3.44 |
21 Nov 2024 | $3.47 | $0.05 | 1.46% | 892,804 | $3.44 | $3.48 | $3.38 |
20 Nov 2024 | $3.42 | $-0.02 | -0.58% | 984,261 | $3.42 | $3.48 | $3.39 |
19 Nov 2024 | $3.44 | $0.04 | 1.18% | 1,264,676 | $3.42 | $3.47 | $3.41 |
18 Nov 2024 | $3.40 | $-0.02 | -0.58% | 917,017 | $3.38 | $3.46 | $3.33 |
15 Nov 2024 | $3.42 | $-0.12 | -3.39% | 1,723,149 | $3.52 | $3.54 | $3.29 |
14 Nov 2024 | $3.54 | $-0.04 | -1.12% | 621,328 | $3.55 | $3.56 | $3.46 |
13 Nov 2024 | $3.58 | $-0.01 | -0.28% | 741,271 | $3.62 | $3.62 | $3.52 |
12 Nov 2024 | $3.59 | $-0.02 | -0.55% | 417,826 | $3.65 | $3.65 | $3.57 |
11 Nov 2024 | $3.61 | $0.01 | 0.28% | 382,917 | $3.55 | $3.69 | $3.55 |
08 Nov 2024 | $3.60 | $-0.06 | -1.64% | 579,535 | $3.65 | $3.74 | $3.58 |
07 Nov 2024 | $3.66 | $-0.01 | -0.27% | 1,280,645 | $3.67 | $3.69 | $3.60 |
06 Nov 2024 | $3.67 | $0.10 | 2.80% | 912,231 | $3.59 | $3.67 | $3.58 |
05 Nov 2024 | $3.57 | $-0.01 | -0.28% | 323,674 | $3.60 | $3.61 | $3.55 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
26 Aug 2024 | Melinda McGrath | Expiry | 247,252 | $694,778 |
As advised by the company. forfeited
|
28 Feb 2024 | Christine Bartlett | Buy | 20,000 | $47,154 |
On-market trade. As per announcement on 05-03-2024
|
20 Dec 2023 | Melinda McGrath | Issued | 395,490 | $901,717 |
Issue of securities. vwap, 880,836 Rights, As per announcement on 04-01-2024
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Michael Thomas Alscher | Non-Executive DirectorNon-Executive Chairman | Dec 2020 |
Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, specialising in high growth companies and certain industry sectors such as healthcare. Michael is the current Chair of Cardno Limited, National Dental Care Limited, 24-7 Healthcare Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited, Green Leaves Early Learning Centres Pty Ltd and Aurora Expeditions Holdings Pty Ltd. Michael's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited, Crumpler Pty Ltd and Intega Group Limited. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles. Michael is a Member of Risk Committee.
|
Dr Leanne Rowe | Non-Executive Director | Apr 2021 |
Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria. She has previously served on a range of boards, including as a Chair of Nexus Hospitals, the Royal Australian College of General Practitioners and Barwon Health (Acting); and as a Non-Executive Director of Japara Healthcare, Medibank Private, I-Med Radiology, the Medical Indemnity Protection Society and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University. Leanne Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria. She has previously served on a range of boards, including as a Chair of Nexus Hospitals, the Royal Australian College of General Practitioners and Barwon Health (Acting); and as a Non-Executive Director of Japara Healthcare, Medibank Private, I-Med Radiology, the Medical Indemnity Protection Society and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University. Leanne
|
Ms Christine Nildra Bartlett | Non-Executive Director | Aug 2023 |
Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council, Chief Executive Women and the Australian Institute of Company Directors. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of risk committee
|
Mr Mark Haberlin | Non-Executive Director | Apr 2021 |
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of risk committee. Other directorships include Layby Group Holdings Limited, April 2020 - present.
|
Ms Melinda Leigh McGrath | Chief Executive OfficerExecutive Director | Dec 2020 |
Ms McGrath has more than 30 years of experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.
|
Ms Eleanor Padman | Company Secretary |
-
|
|
Eleanor Padman | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 52,928,564 | 26.22% |
J P Morgan Nominees Australia Pty Limited | 40,768,093 | 20.20% |
HSBC Custody Nominees (Australia) Limited i | 23,098,892 | 11.44% |
National Nominees Limited | 19,505,294 | 9.66% |
Neweconomy Com Au Nominees Pty Limited | 5,563,328 | 2.76% |
Warbont Nominees Pty Ltd | 4,488,571 | 2.22% |
BNP Paribas Noms (Nz) Ltd | 4,381,212 | 2.17% |
BNP Paribas Nominees Pty Ltd | 2,282,496 | 1.13% |
Melinda McGrath | 2,173,867 | 1.08% |
ECapital Nominees Pty Limited | 2,012,539 | 1.00% |
UBS Nominees Pty Ltd | 1,965,408 | 0.97% |
HSBC Custody Nominees (Australia) Limited ii | 1,864,257 | 0.92% |
ACL Employee Share Trusco Pty Ltd | 1,445,624 | 0.72% |
First Samuel Ltd ACN 086243567 | 1,273,234 | 0.63% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 1,254,600 | 0.62% |
Hsbc Custody Nominees (Australia) Limited-Gsi Eda | 1,225,450 | 0.61% |
Mr Nicholas Barry Debenham & Mrs Annette Cecilia Debenham | 1,010,800 | 0.50% |
Zachary Investments Pty Ltd | 1,000,000 | 0.50% |
BNP Paribas Noms Pty Ltd | 829,947 | 0.41% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 790,918 | 0.39% |